MX339759B - Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. - Google Patents

Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.

Info

Publication number
MX339759B
MX339759B MX2013001204A MX2013001204A MX339759B MX 339759 B MX339759 B MX 339759B MX 2013001204 A MX2013001204 A MX 2013001204A MX 2013001204 A MX2013001204 A MX 2013001204A MX 339759 B MX339759 B MX 339759B
Authority
MX
Mexico
Prior art keywords
prevention
treatment
compounds
inflammatory diseases
ocular inflammatory
Prior art date
Application number
MX2013001204A
Other languages
English (en)
Other versions
MX2013001204A (es
Inventor
Annat Jocelyne
Huguet Helene-Celine
Lacombe Olivier
Lebreton Luc
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1056290A external-priority patent/FR2963238B1/fr
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Publication of MX2013001204A publication Critical patent/MX2013001204A/es
Publication of MX339759B publication Critical patent/MX339759B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere al uso de los compuestos de la fórmula (I) y sus sales aceptables farmacéuticamente para el tratamiento o la prevención de enfermedades inflamatorias oculares, en particular para el tratamiento y/o prevención de la uveítis, conjuntivitis severa, síndrome de ojo seco o retinopatía diabética.
MX2013001204A 2010-07-29 2011-07-08 Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. MX339759B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1056290A FR2963238B1 (fr) 2010-07-29 2010-07-29 Derives de 15-desoxyspergualine pour le traitement et/ou la prevention des maladies inflammatoires oculaires
FR1152836 2011-04-01
PCT/FR2011/051639 WO2012013884A1 (fr) 2010-07-29 2011-07-08 Composes pour le traitement/la prevention des maladies inflammatoires oculaires

Publications (2)

Publication Number Publication Date
MX2013001204A MX2013001204A (es) 2013-08-15
MX339759B true MX339759B (es) 2016-06-08

Family

ID=44514307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001204A MX339759B (es) 2010-07-29 2011-07-08 Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.

Country Status (11)

Country Link
US (1) US20130190278A1 (es)
EP (1) EP2598131A1 (es)
JP (1) JP5878172B2 (es)
KR (1) KR20130099926A (es)
CN (1) CN103037857B (es)
AU (1) AU2011284589B2 (es)
BR (1) BR112013002144A2 (es)
CA (1) CA2806942C (es)
MX (1) MX339759B (es)
RU (1) RU2582609C2 (es)
WO (1) WO2012013884A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3065551A4 (en) * 2013-11-04 2017-08-09 Becton, Dickinson and Company Immunomodulatory potential of a multipotent stromal cell (msc) population
SG11201703572SA (en) * 2014-12-02 2017-05-30 Regeneron Pharma Animal model for dry eye and methods of use of such animals
US10456347B2 (en) 2015-11-24 2019-10-29 Bmi Korea Co., Ltd Composition for injection of hyaluronic acid, containing hyaluronic acid derivative and DNA fraction, and use thereof
WO2017188818A1 (en) * 2016-04-29 2017-11-02 Enceladus Pharmaceuticals B.V. Liposomal corticosteroids for topical injection in inflamed lesions or areas
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
RU2633349C1 (ru) * 2016-11-24 2017-10-11 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей
WO2019108602A1 (en) 2017-11-28 2019-06-06 University Of Florida Research Foundation Methods and compositions for retinal drug delivery
WO2020098630A1 (en) * 2018-11-14 2020-05-22 Zhuhai Qiwei Bio-Technology Ltd. Animal models, screening methods, and treatment methods for intraocular diseases or disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2716452B1 (fr) * 1994-02-24 1996-05-10 Fournier Ind & Sante Analogues de la 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
DE60328161D1 (de) * 2002-01-11 2009-08-13 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
JP2006176457A (ja) * 2004-12-24 2006-07-06 Wakamoto Pharmaceut Co Ltd 医薬用水性液状組成物

Also Published As

Publication number Publication date
RU2582609C2 (ru) 2016-04-27
MX2013001204A (es) 2013-08-15
WO2012013884A1 (fr) 2012-02-02
BR112013002144A2 (pt) 2016-05-24
CA2806942C (en) 2019-06-25
AU2011284589B2 (en) 2015-07-16
CA2806942A1 (en) 2012-02-02
AU2011284589A1 (en) 2013-02-21
US20130190278A1 (en) 2013-07-25
KR20130099926A (ko) 2013-09-06
CN103037857A (zh) 2013-04-10
EP2598131A1 (fr) 2013-06-05
JP2013532678A (ja) 2013-08-19
CN103037857B (zh) 2016-02-10
JP5878172B2 (ja) 2016-03-08
RU2013108857A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
MX339759B (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
IN2015DN01156A (es)
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201390198A1 (ru) Гетероциклическое соединение
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX2014012695A (es) Derivados de isoindolona.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
SG195257A1 (en) Anti-thrombotic compounds
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
EA201290229A1 (ru) Производные спиролактама и их применение
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
EA201001427A1 (ru) Тиазолилдигидроиндазолы
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
MX2009012761A (es) Neramexano para el tratamiento de nistagmo.
EA201201049A1 (ru) 5-алкинилпиримидины и их применение в качестве ингибиторов киназы
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.

Legal Events

Date Code Title Description
FG Grant or registration